Related Experiment Videos
Medical management of Lennox-Gastaut syndrome
Aspasia Michoulas1, Kevin Farrell
1Division of Neurology, Department of Pediatrics, University of British Columbia and British Columbia's Children's Hospital, Vancouver, British Columbia, Canada.
Insights
Lennox-Gastaut syndrome (LGS) is a severe epilepsy in children. Current treatments offer limited seizure control, highlighting the need for better understanding and novel therapeutic approaches.
Area of Science:
- Neurology
- Pediatric Epilepsy
Background:
- Lennox-Gastaut syndrome (LGS) affects 3% of children with epilepsy, presenting with diverse seizures, specific EEG patterns, and poor developmental outcomes.
- Established treatments like felbamate, lamotrigine, topiramate, and rufinamide show limited efficacy, with no single drug providing complete seizure control.
Purpose of the Study:
- To review the current understanding and treatment landscape of Lennox-Gastaut syndrome.
- To identify current first-line drug therapies and explore alternative treatments like the ketogenic diet.
Main Methods:
- Review of randomized controlled trials and Cochrane reviews on LGS treatments.
- Analysis of expert panel recommendations for first-line therapies.
- Evaluation of the ketogenic diet as a potential treatment.
Main Results:
- Adjunctive therapies demonstrate moderate seizure reduction but rarely achieve complete control.
- Valproate, lamotrigine, and topiramate are recommended as first-line treatments by expert panels.
- The ketogenic diet may offer superior efficacy compared to antiepileptic drugs and warrants early consideration.
Conclusions:
- Optimal treatment for LGS remains uncertain, emphasizing the need for improved management strategies.
- A deeper understanding of LGS pathophysiology and development of animal models are crucial for advancing new treatments.
Abstract:
Lennox-Gastaut syndrome occurs in 3% of children with epilepsy and is characterized by multiple seizure types, slow spike-and-wave discharges and a poor prognosis for seizure control and cognitive development. Although randomized controlled trials of adjunctive felbamate, lamotrigine, topiramate and rufinamide have demonstrated a > or =50% reduction in seizure frequency, very few children achieve complete seizure control and a Cochrane review of the treatment of Lennox-Gastaut syndrome concluded that the optimum treatment was uncertain and that no drug has been shown to be highly efficacious. Valproate, lamotrigine and topiramate were considered recently by expert panels in the US and Europe to be the first-line drugs. The ketogenic diet may be more effective than antiepileptic drugs and should be considered early in treatment. An improvement in the management of Lennox-Gastaut syndrome requires a better understanding of the pathophysiology of this disorder and the development of animal models in which to test new compounds.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:24Mania and Antimanic Drugs: Overview
01:26Angina IV: Management
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: